133 related articles for article (PubMed ID: 8768828)
1. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.
Copinschi G; Van Onderbergen A; L'Hermite-Balériaux M; Mendel CM; Caufriez A; Leproult R; Bolognese JA; De Smet M; Thorner MO; Van Cauter E
J Clin Endocrinol Metab; 1996 Aug; 81(8):2776-82. PubMed ID: 8768828
[TBL] [Abstract][Full Text] [Related]
2. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
Codner E; Cassorla F; Tiulpakov AN; Mericq MV; Avila A; Pescovitz OH; Svensson J; Cerchio K; Krupa D; Gertz BJ; Murphy G
Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
Chapman IM; Bach MA; Van Cauter E; Farmer M; Krupa D; Taylor AM; Schilling LM; Cole KY; Skiles EH; Pezzoli SS; Hartman ML; Veldhuis JD; Gormley GJ; Thorner MO
J Clin Endocrinol Metab; 1996 Dec; 81(12):4249-57. PubMed ID: 8954023
[TBL] [Abstract][Full Text] [Related]
4. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles.
Jacks T; Smith R; Judith F; Schleim K; Frazier E; Chen H; Krupa D; Hora D; Nargund R; Patchett A; Hickey G
Endocrinology; 1996 Dec; 137(12):5284-9. PubMed ID: 8940347
[TBL] [Abstract][Full Text] [Related]
5. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
Murphy MG; Plunkett LM; Gertz BJ; He W; Wittreich J; Polvino WM; Clemmons DR
J Clin Endocrinol Metab; 1998 Feb; 83(2):320-5. PubMed ID: 9467534
[TBL] [Abstract][Full Text] [Related]
6. Increases in circulating insulin-like growth factor I levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation.
Schleim KD; Jacks T; Cunningham P; Feeney W; Frazier EG; Niebauer GW; Zhang D; Chen H; Smith RG; Hickey G
Endocrinology; 1999 Apr; 140(4):1552-8. PubMed ID: 10098487
[TBL] [Abstract][Full Text] [Related]
7. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
Chapman IM; Pescovitz OH; Murphy G; Treep T; Cerchio KA; Krupa D; Gertz B; Polvino WJ; Skiles EH; Pezzoli SS; Thorner MO
J Clin Endocrinol Metab; 1997 Oct; 82(10):3455-63. PubMed ID: 9329386
[TBL] [Abstract][Full Text] [Related]
8. Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles.
Hickey GJ; Jacks TM; Schleim KD; Frazier E; Chen HY; Krupa D; Feeney W; Nargund RP; Patchett AA; Smith RG
J Endocrinol; 1997 Feb; 152(2):183-92. PubMed ID: 9071975
[TBL] [Abstract][Full Text] [Related]
9. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
Khorram O; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
[TBL] [Abstract][Full Text] [Related]
10. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
Murphy MG; Bach MA; Plotkin D; Bolognese J; Ng J; Krupa D; Cerchio K; Gertz BJ
J Bone Miner Res; 1999 Jul; 14(7):1182-8. PubMed ID: 10404019
[TBL] [Abstract][Full Text] [Related]
11. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
Svensson J; Lönn L; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Boseaus I; Sjöström L; Bengtsson BA
J Clin Endocrinol Metab; 1998 Feb; 83(2):362-9. PubMed ID: 9467542
[TBL] [Abstract][Full Text] [Related]
12. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study.
Bellantoni MF; Vittone J; Campfield AT; Bass KM; Harman SM; Blackman MR
J Clin Endocrinol Metab; 1996 Aug; 81(8):2848-53. PubMed ID: 8768841
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-1 and growth hormone (GH) levels in canine cerebrospinal fluid are unaffected by GH or GH secretagogue (MK-0677) administration.
Prahalada S; Block G; Handt L; DeBurlet G; Cahill M; Hoe CM; van Zwieten MJ
Horm Metab Res; 1999; 31(2-3):133-7. PubMed ID: 10226793
[TBL] [Abstract][Full Text] [Related]
14. Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates.
Williams RM; Yuen K; White D; Mallard B; Dalton RN; Acerini CL; Dunger DB
Clin Endocrinol (Oxf); 2006 Oct; 65(4):439-45. PubMed ID: 16984235
[TBL] [Abstract][Full Text] [Related]
15. Levels of growth hormone, insulin-like growth factor-I (IGF-I) and -II, IGF-binding protein-1 and -3, and cortisol in prednisone-treated children with growth retardation after renal transplantation.
Hokken-Koelega AC; Stijnen T; de Muinck Keizer-Schrama SM; Blum WF; Drop SL
J Clin Endocrinol Metab; 1993 Oct; 77(4):932-8. PubMed ID: 7691864
[TBL] [Abstract][Full Text] [Related]
16. Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak growth hormone (GH) release following short-term low-dose GH administration in young healthy adults.
Yuen K; Frystyk J; Umpleby M; Fryklund L; Dunger D
J Clin Endocrinol Metab; 2004 Aug; 89(8):3956-64. PubMed ID: 15292333
[TBL] [Abstract][Full Text] [Related]
17. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group.
Dall R; Longobardi S; Ehrnborg C; Keay N; Rosén T; Jørgensen JO; Cuneo RC; Boroujerdi MA; Cittadini A; Napoli R; Christiansen JS; Bengtsson BA; Sacca L; Baxter RC; Basset EE; Sönksen PH
J Clin Endocrinol Metab; 2000 Nov; 85(11):4193-200. PubMed ID: 11095453
[TBL] [Abstract][Full Text] [Related]
18. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
Svensson J; Ohlsson C; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Baylink D; Mohan S; Bengtsson BA
J Bone Miner Res; 1998 Jul; 13(7):1158-66. PubMed ID: 9661080
[TBL] [Abstract][Full Text] [Related]
19. Nocturnal augmentation of growth hormone (GH) secretion is preserved during repetitive bolus administration of GH-releasing hormone: potential involvement of endogenous somatostatin--a clinical research center study.
Jaffe CA; Turgeon DK; Friberg RD; Watkins PB; Barkan AL
J Clin Endocrinol Metab; 1995 Nov; 80(11):3321-6. PubMed ID: 7593445
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects.
Aloi JA; Gertz BJ; Hartman ML; Huhn WC; Pezzoli SS; Wittreich JM; Krupa DA; Thorner MO
J Clin Endocrinol Metab; 1994 Oct; 79(4):943-9. PubMed ID: 7962302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]